---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117760"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:13:55.185267+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health Q3 prescription revenue $3.1M (+412% YoY); net loss widens to $12.5M

## Summary
- Prescription product net revenue $3.1M in Q3 2022, up 8.2% QoQ and 412% YoY vs $0.6M.
- Net loss $12.5M ($0.12/sh) vs $12.2M loss in Q3 2021; operating loss $9.9M vs $9.5M.
- R&D expense rose to $5.9M from $3.3M driven by Phase 3 crofelemer CTD trial.
- OnTarget Phase 3 CTD trial targets enrollment completion in Q2 2023.
- Non-GAAP EBITDA loss $8.5M, flat YoY; no guidance provided.

## SEC filing metadata
- accession: 0001104659-22-117760
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/0001104659-22-117760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/tm2230421d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117760
- JSON: https://secwatch.observer/filing/0001104659-22-117760.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117760.txt

## Key facts
- Earnings Releases
  Jaguar Health, Inc. reported third quarter 2022 results: revenue approximately $3.1 million.
  - Period: third quarter 2022
  - Revenue: approximately $3.1 million
  - Result: reported results
  source text: The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $3.1 million in the third quarter of 2022, representing an increase of 8.2% over prescription product net revenue in the second quarter of 2022, which totaled approximately $2.9 million, and an increase of approximately 412% over Mytesi net revenue in the third quarter of 2021, which totaled approximately $0.6 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/0001104659-22-117760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.